Abstract
In recent years estramustine phosphate (EMP) or Estracyt® has become an alternative to standard estrogen therapy in a number of centres. It has been debated whether estramustine is just one variant of estrogen or if it has another anticancer effect in addition.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Huggins C, Scott WW, Hodges CV: Studies on prostatic cancer. Ill The effects of fever, desoxycorticosterone, and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 1941 (46):997
Byar DP: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973 (32):1126
Scott WW, Menow M, Walsh PC: Hormonal therapy of prostatic cancer. Cancer 1980 (45):1929
Plym-Forshell G, Müntzing J, Ek A, Lindstedt E, Dencker H: The absorption, metabolism and excretion of Estracyt (NSC 89199) in patients with prostatic cancer. Invest Urol 1976 (14):128, 1976
Gunnarsson PO, Plym-Forshell G: Clinical pharmacokinetics of estramustine phosphate. Urology 1984 (23 Suppl 6):22
Jönsson G, Olsson A, Luttrop W, Cekan C, Purvis K, Diczfalusy E: Treatment of prostatic carcinoma with various types of estrogen derivatives. Vitamines and Hormones 1975 (33):351
Kadohama N, Kirdani RY, Murphy GP, Sandberg AA: 5-alpha-reductase as a target enzyme for anti-prostatic drugs in organ culture. Oncology 1977 (34):123
Kirdani RY, Müntzing J, Varkarakis JM, Murphy GP, Sandberg AA: Studies on the antiprostatic action of Estracyt, a nitrogen mustard of estradiol. Cancer Res 1974 (34):1031
Hoisaeter PÄ: Incorporation of 3H-thymidine into rat ventral prostate in organ culture. Invest Urol 1975 (12):479
Hartley-Asp B, Gunnarsson PO: Growth and cell survival following treatment with estramustine, nornitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 1982 (127):818
Müntzing J, Kirdani RY, Saroff J, Murphy GP, Sandberg AA: Inhibitory effects of Estracyt on R-3327 rat prostatic carcinoma. Urology 1977 (10):439
Hartley-Asp B: Estramustine induced mitotic arrest in two human prostatic carcinoma cell lines, DU 145 and PC- 3. Prostate 1984 (5):93
Hartley-Asp B: Microtubule assembly in vitro as an aid in the study of aneuploidy. Aneuploidy I: Incidence and etiology. 1987 (in press)
Neide HJ, Flüchter SH, Hartmann R, Bichler KH: Immunhistologischer Nachweis des Estramustin-bindenden Proteins (EMBP) in der Prostata. In: Harzmann et al (eds) Experimentelle Urologie. Springer Verlag. Berlin, Heidelberg 1985, p 332.
Flüchter SH, Neide HJ, Björk P, Müntzing J, Bichler KJ: Estramustine-binding protein (EMBP) in human prostatic cancer tissue. Effect of anti-cancer treatment. 1987 (in press)
Harper ME, Fahmy AR, Pierrepoint CG, Griffiths K: The effect of some stilbestrol compounds on DNA polymerase from human prostatic tissues. Steroids 1970 (15):89
Daehlin L: On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma. Scand J Urol Nephrol. 1985 (Suppl 91):21
Eriksson A, Carlström K, Collste L: Estrogen treatment or orchidectomy in prostate cancer: Effects on testicular and adrenal androgens and on total androgen activity, (submitted)
Edsmyr F, Andersson L, Könyves I: Estramustine phosphate (Estracyt): Experimental studies and clinical experience. In: Jacobi and Hohenfellner (eds) Prostate cancer. Williams and Wilkins, Baltimore, London 1982, p 253.
Andersson L, Berlin T, Boman J et al: Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol 1980 (Suppl 55):143
Benson RC, Gill GM: Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer. Am J Clin Oncol (CCT) 1986 (9):341
Smith PH, Suciu S, Robinson MRG et al: A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: Final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 1986 (136):619
Hauchecorne J: Estramustine phosphate versus diethylstilbestrol. Etude comparative ä propos de 115 malades. J Urol (Paris) 1987 (in press)
Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 1986 (28):36
Leistenschneider W, Nagel R: Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA-cytophotometry. Eur Urol 1980 (6):111
Hedlund PO, Gustafson H, Sjögren S: Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients. Scand J Urol Nephrol 1980 (Suppl 55):103
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Andersson, L. (1988). Estrogens and Estramustine Phosphate. In: Denis, L. (eds) The Medical Management of Prostate Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73238-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-73238-6_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73240-9
Online ISBN: 978-3-642-73238-6
eBook Packages: Springer Book Archive